Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Taken at least one dose of double-blind medication during study IH 001 and either completed study IH 001 or were withdrawn due to reasons other than an AE considered related to study treatment~2. Male or female subjects on active haemodialysis, aged 18 years or over~3. Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication;~4. Willing to avoid any intentional changes in diet such as fasting, dieting or overeating;~5. Willing to maintain their usual type and dose of Vitamin D supplementation.~Exclusion Criteria:~1. Participation in any other clinical trial using an investigational product or device within the previous 4 months;~2. A significant history of alcohol, drug or solvent abuse in the opinion of the investigator;~3. Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn;~4. Clinically significant laboratory findings (for this subject population) in the opinion of the investigator.~5. Any malignancy with the exception of basal cell carcinoma;~6. A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction;~7. A significant illness in the 4 weeks before screening;~8. Taking medication for seizures;~9. A history of haemochromatosis;~10. A history of serum ferritin concentration of ≥ 1000 ng/mL (excluding transient, treatment-induced ferritin elevation);~11. A history of dysphagia or swallowing disorders;~12. Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device;~13. Current haemoglobin concentration of \< 10.00 g/dL;~14. Allergy to the IMP or its constituents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fermagate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).